Sulfonylurea-Induced Hypoglycemia in a Patient With Cirrhosis
| Autor: | John Millard, Charles Scott Buess, Corey Braet, Yasmine Hussein Agha, Ali Taleb |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Alcoholic liver disease Cirrhosis medicine.drug_class liver cirrhosis 030204 cardiovascular system & hematology Hypoglycemia Chronic liver disease Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine Internal Medicine Medicine Hypoalbuminemia business.industry Endocrinology/Diabetes/Metabolism General Engineering nutritional and metabolic diseases Type 2 Diabetes Mellitus medicine.disease Sulfonylurea sulfonylurea compounds drug contraindications business 030217 neurology & neurosurgery Glipizide medicine.drug |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| DOI: | 10.7759/cureus.8513 |
| Popis: | Type 2 diabetes mellitus is highly prevalent among patients with cirrhosis. The pharmacological management of this disease in patients with chronic liver disease remains controversial, however. Insulin secretagogues such as sulfonylureas are associated with a high risk of hypoglycemia among diabetics. In patients with cirrhosis, this risk is more pronounced due to decreased hepatic clearance, concurrent alcoholism, hypoalbuminemia, and acute liver decompensation. In this case report, we present a case of severe refractory hypoglycemia secondary to glipizide in a patient with alcoholic cirrhosis. We believe that the use of sulfonylureas in this patient population should be contraindicated to avoid debilitating neurologic damage and death following hypoglycemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|